KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Long-Term Deferred Tax: 2012-2020

Historic Long-Term Deferred Tax for Ionis Pharmaceuticals (IONS) over the last 2 years, with Sep 2020 value amounting to $307.7 million.

  • Ionis Pharmaceuticals' Long-Term Deferred Tax rose 7.98% to $307.7 million in Q3 2020 from the same period last year, while for Sep 2020 it was $307.7 million, marking a year-over-year increase of 7.98%. This contributed to the annual value of $305.6 million for FY2019, which is 5.08% up from last year.
  • Ionis Pharmaceuticals' Long-Term Deferred Tax amounted to $307.7 million in Q3 2020, which was up 0.57% from $306.0 million recorded in Q2 2020.
  • In the past 5 years, Ionis Pharmaceuticals' Long-Term Deferred Tax ranged from a high of $309.6 million in Q1 2020 and a low of $276.4 million during Q2 2019.
  • Over the past 3 years, Ionis Pharmaceuticals' median Long-Term Deferred Tax value was $298.2 million (recorded in 2018), while the average stood at $294.8 million.
  • Data for Ionis Pharmaceuticals' Long-Term Deferred Tax shows a peak YoY rose of 11.67% (in 2020) over the last 5 years.
  • Quarterly analysis of 3 years shows Ionis Pharmaceuticals' Long-Term Deferred Tax stood at $290.8 million in 2018, then increased by 5.08% to $305.6 million in 2019, then rose by 7.98% to $307.7 million in 2020.
  • Its Long-Term Deferred Tax stands at $307.7 million for Q3 2020, versus $306.0 million for Q2 2020 and $309.6 million for Q1 2020.